Company: LHI
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006939
Chunk: 18

Company: Living Homeopathy International Ltd.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 18
---
 assessment of the assignments, examination papers and supervisions.

Strategies

Diversify our sales channel to support market development

We plan to
diversify our sales channels by developing our online flagship store on Tmall Global, an e-commerce platform for international
businesses to directly sell our brand-name goods to consumers in mainland China, which was recently set up in June 2024. The key
products that we expect to sell through our online flagship store are our homeopathic co-remedies products.We have
engaged a third-party service provider to assist us in developing the operations of this online flagship store, including virtual
store design, maintenance, product management, marketing and customer attracting, data collection and analysis and customer service.
As of the date of this prospectus, given that we are at an early stage of developing and marketing this online store, it has not
generated any sales to external customers. See “Risk Factors – Risks related to our Business and Industry -- Our business is heavily regulated and our industry may be subject to increasingly tightened regulatory requirements and scrutiny in the main markets where we operate and the new markets we will sell our products, which could potentially adversely affect our business growth, financial condition and results of operations” on page 17 of this prospectus for more details.

<div align='center'>2</div>

Promoting market regularization and standardization We are committed to promoting the regularization and standardization of the homeopathy market in Hong Kong and mainland China. The standardization of the homeopathy market practice in Hong Kong and mainland China is still under development. We plan to work with regional homeopathy-related institutes, medical schools, and other organizations to promote market awareness of homeopathy and establishment of market regulations and standard. Summary of Risk Factors Living Homeopathy is a Cayman Holding company that conducts its business operations through its Hong Kong Subsidiary, Living Homeopathy Hong Kong. The PRC government may exert more control over offerings conducted overseas and/or foreign investment in issuers like us. Such governmental actions, if and when occur: (i) could significantly limit or completely hinder our ability to continue our operations; (ii) could significantly limit or completely hinder our ability to offer or continue to offer our securities to investors; and (iii) may cause the value of such securities to significantly decline or be worthless. Investing in Living Homeopathy’s Class A Ordinary Shares involves significant risks. You should carefully consider all of the information in this prospectus before making an investment in the Class A Ordinary Shares. Below please